As these mutations are associated with treatment resistance, their presence may counteract the lower risk clinicopathologic features associated with ELF3/HNF4A up-regulated cancers and could explain the lack of statistically significant differences in survival outcomes [38]. The gene discussed is HNF4A; the disease is cancer.